Introduction
Hypokalemia is a common electrolyte abnormality encountered in the clinical setting. It can lead to cardiac arrhythmias, muscle weakness, and rhabdomyolysis (1) (2) (3) (4) (5) . The causes of hypokalemia can be broadly classified into decreased intake, increased entry into cells due to causes such as increase in extracellular pH, increased β-adrenergic activity or insulin administration, and increased losses from sweating, and the gastrointestinal or renal systems (6) . In addition to the diagnosis and treatment of the underlying cause(s) of hypokalemia, replacement of the potassium deficit is necessary when managing these patients. This urgency of replacement therapy will depend on the severity of hypokalemia, the rate of decline in serum potassium concentration, and associated comorbidities of the patient. Potassium can be administered as potassium chloride, potassium phosphate, potassium bicarbonate potassium gluconate or its precursors (potassium citrate, potassium acetate) (7, 8) . Potassium chloride has been the mainstay of replacement therapy for two main reasons:
• The serum potassium concentration increases at a faster rate than other formulation as chloride is primarily an extracellular anion, thereby promoting maintenance of the administered potassium in the extracellular fluid (9) .
• Patients with hypokalemia are often chloride-depleted. This chloride-depleted state will contribute to metabolic alkalosis by enhancing renal bicarbonate reabsorption that leads to potassium wasting, as sodium is reabsorbed in exchange for secreted potassium rather than with chloride (10, 11) .
Intravenous replacement should be used in patients with severe symptomatic hypokalemia (less than 2.5 mmol/L) and in patients with less severe hypokalemia who are unable to take oral medications. The most common problem associated with potassium chloride infusion is pain. The occurrence of pain has been reported in up to 60% of patients receiving intravenous replacement (12) , resulting in patient's refusal of the prescribed therapy (13) . While the exact mechanism of action is not known, possible causes include direct chemical and/or osmotic irritation of the intima and mechanical distension from volume of drug injected (14) . Prevention or reduction of pain can be achieved by running potassium chloride at an infusion rate below 20 mmol/hour (15) , injecting into large vein using a large bore cannula, adding a diluent (e.g., 0.9% normal saline) during the infusion process, and applying an ice pack.
Previous studies have demonstrated the efficacy of lignocaine in alleviating pain during potassium chloride infusion both immediately and over an infusion time of up to 2 hours (14-16). However, the varying doses of lignocaine, small sample size, and subsequent reports of safety issues have limited the prevalent use of lignocaine in clinical practice. Safety issues have been attributed to the different formulations of lignocaine available and the extra step of preparation which led to an increased likelihood of medical error (17) . Concerns have also been raised about the potential of lignocaine to mask phlebitis. More than a decade later, we embarked on this study to relook at the efficacy and safety related to the use of lignocaine in reducing pain during potassium chloride infusion. We hope that our findings will offer clinicians the option of a fairly simple intervention that will address the issue of pain experienced by patients during potassium chloride infusion.
Materials and Methods

Setting
This study was conducted in an Emergency Department (ED) in Singapore that sees about 135,000 patients a year.
Design
A prospective observational study of the effect of lignocaine on pain during potassium chloride infusion was recorded in a continuous quality improvement database from March 2015 to May 2016. Patients were recruited by consecutive sampling. They were included if the attending ED physician ordered intravenous potassium replacement with potassium chloride. Patients with a history of epilepsy, cardiac arrhythmia, and sensitivity to lignocaine were excluded from the study. Baseline characteristics of age, gender, concentration of serum potassium, duration of potassium chloride infusion, and concurrent run of normal saline were recorded prior to the initiation of lignocaine.
Potassium chloride was given as a premixed solution containing 10 mmol of potassium chloride in 100 mL of water for injection. This commercially available preparation was routinely used for potassium chloride infusion as per departmental protocol. Patients who received lignocaine were given a 3 mL bolus of 1% solution a minute before the start of the potassium chloride infusion. This intervention was unblinded to the patient and attending staff. Patients were put on cardiac monitoring during the period of intravenous replacement if they had received lignocaine.
All doctors and nurses working in the ED were briefed on the lignocaine protocol. As this practice was recommended but not a standard-of-care in the department, the decision to administer lignocaine to the patient was left to the discretion of the attending physician.
Outcome
The primary outcome was to determine the efficacy of lignocaine in reducing pain experienced during potassium chloride infusion. The qualitative occurrence of self-reported pain was tracked instead of a quantitative pain score during the potassium chloride infusion. This was chosen as a practical outcome measure, as any occurrence of pain would necessitate intervention from the attending staff to help the patient tolerate the infusion. These interventions were dependent on the attending physician and included applying ice pack, slowing down the initial infusion rate, and stopping the infusion due to patient's refusal. The secondary outcome was to determine the adverse events associated with intravenous lignocaine use for this purpose. Adverse events were defined as lignocaine toxicity, cardiac arrhythmia, masking of phlebitis, and medication error. Occurrence of any pain or adverse event was recorded by the attending staff and subsequently traced from review of the patients' case records.
Sample size
On the basis of the previous study by Lim et al. (14) , the incidence of pain in patients who did not receive lignocaine was 85.7% compared with 28.6% when lignocaine was given. For a reduction of at least 50% in the occurrence of pain in patients who received lignocaine prior to the potassium chloride infusion, a sample size of 22 with equal numbers in each arm was required to power our study (α=0.05, β=0.2, power=0.8).
To increase the robustness of the study, patients were enrolled in the study until the end of the quality improvement initiative that would recruit 50 patients in each arm of the study as determined a priori.
Statistical analysis
To control for selection bias in the assignment of subjects to treatment due to the baseline characteristics, stabilized inverse probability of treatment weights (IPTWs) were used in the analysis to estimate the efficacy of lignocaine on pain outcome. IPTWs were derived using weights on the basis of propensity scores to create a pseudo-sample in which the distribution of the measured baseline covariates was independent of the treatment assignment (18) . Propensity scores of the subjects were estimated using the multivariable logistic regression where the status of treatment was regressed on the measured baseline covariates. Stabilized IPTWs will reduce variability due to instability in estimation that could be induced either by those treated subjects with low propensity scores or untreated subjects with high propensity scores (18, 19) . Absolute standardized difference was calculated for each of the baseline covariates to assess the balance be- 
Results
One hundred eligible patients were enrolled consecutively in the study to meet the sample size of 50 patients in the treatment group where lignocaine was given prior to the initiation of potassium chloride and another 50 patients in the control group with no lignocaine given.
The baseline demographics and clinical characteristics of the 100 patients are presented in Table 1 . The average age of patients included in the study was 64.5 (±19.3) years. Majority of the patients were females (70%). Eighty-one percent of all patients required more than 1 hour of potassium chloride infusion, and 79% of the patients required concurrent run of normal saline due to their presenting medical conditions. The average serum potassium concentration of patients was 2.7 (±0.4) mmol/L.
Prior to stabilized weights adjustment, all covariates, except gender, had an absolute standardized difference of more than 0.1, with a maximum of 0.55 for the mean serum potassium concentration (p=0.007) ( Table 2) . On average, patients in the lignocaine group tend to be younger (mean age, 63.0 vs. 66.0 years) and had a higher level of serum potassium concentration (2.8 vs. 2.6 mmol/L). The proportion of patients who required potassium chloride infusion of more than 1 hour was lower in the lignocaine group than in the control group (74.0% vs. 86.0%). More patients in the lignocaine group had concurrent run of normal saline solution during the potassium chloride infusion (84.0% vs. 74.0%). There was no absolute difference in the proportion of gender between the two groups.
After stabilized weights adjustment, the resultant sample size was 98, with 49 patients in each group. There were no significant differences in the baseline covariates between the two groups. The absolute standardized differences for all covariates in the weighted sample ranged from a maximum of 0.1 to a minimum of 0.03. Balance of baseline covariates between the lignocaine and the control group was achieved in the stabilized weights adjusted sample.
The efficacy of lignocaine on pain was estimated on the basis of the weighted sample where the assignment of patients to lignocaine was independent on the patients' baseline characteristics. The proportion of patients experiencing pain was significantly higher in the control group where no lignocaine was given prior to the potassium chloride infusion (38.8% vs. 16.3%, p=0.013) (Figure 1 ).
The absolute risk reduction was 22.5% and the relative risk of pain associated with lignocaine was 0.42 (95% C.I., 0.20-0.87, p=0.013). In other words, the risk of experiencing pain for patients who were not assigned to the lignocaine group was 2.4 times the risk of those who were given lignocaine. The numbers needed to treat was 5 (95% C.I., [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , suggesting that on average, for every five patients who were treated with lignocaine prior to the initiation of potassium chloride infusion, one will benefit from the treatment.
There were no adverse events associated with the lignocaine protocol used in this study, particularly the occurrence of cardiac arrhythmias, lignocaine toxicity, and medication errors. (14) used 3 mL of 1% (30 mg) lignocaine as a bolus 1 minute before starting a 20 mmol potassium chloride diluted in 100 ml dextrose 5% infusion which was administered over 2 hours. Morrill et al. (15) used 10 mg of lignocaine added to 10 mmol of potassium chloride in 50 ml of dextrose 5% which was ran over 1 hour. Pucino et al. (16) used 50 mg of lignocaine added to 20 mmol of potassium chloride in 50 ml of dextrose 5% which was administered over 2 hours. The preparation of potassium chloride used in our institution was 10 mmol in 100 mL of water for injection, which was less concentrated than the solutions used in previous studies. Therefore, the incidence of pain in our patients without lignocaine was 38.8%, lower than the 60% reported in literature. To ensure that the lignocaine dose we used was effective in controlling pain and had minimal risk for adverse event, we decided to use 3 mL of 1% lignocaine for in our study. Furthermore, Lim et al. (14) has shown that this dose of lignocaine was effective for pain control both immediately and throughout a 2-hour infusion period, attributable to the duration of action of lignocaine [t 1/2 , 80-108 minutes (20, 21) ]. With the increased in sample size, our study had shown that lignocaine was able to reduce to pain associated with potassium chloride infusion. At S$0.74 per vial and a number needed to treat of 5, this intervention was inexpensive, in addition to being safe at the study regimen.
Unweighted
We would want to highlight that the technique of slow intravenous push when administering the bolus lignocaine dose was important for anesthetizing the nerves fibers that supply the veins. A rapid bolus would deliver the drug systematically rather than allowing lignocaine to act locally and may render the lignocaine bolus ineffective.
Intervention needed
Application of ice pack was done more commonly in 71.4% patients as compared to slowing down of infusion rate in 25% patients who experienced pain. It was unlikely that the attending ED physician would agree to slow down the infusion rate as the first measure after making the decision to initiate intravenous replacement therapy for severe, symptomatic hypokalemia. Our study did not standardize the use of a large vein (e.g., cubital fossa) or a particular cannula size as in previous studies. By leaving this to the attending ED physicians, a pragmatic trial would demonstrate the efficacy of lignocaine in reducing pain during potassium chloride infusion.
Adverse outcomes
While there was genuine concern for potential adverse events from lignocaine use, this likelihood was low at the prescribed dose of 30 mg. For an average 70 kg adult, this was 0.4 mg/kg, way less than the toxic dose of 3 mg/kg for lignocaine where cardiac arrhythmias and other features of lignocaine toxicity ranging from circumoral numbness to seizures may occur. To address the concern of cardiac arrhythmias, our patients were put on cardiac monitoring throughout the period of infusion during the study. No arrhythmia was noted with this dosage of lignocaine. Therefore, the routine use of cardiac monitoring with lignocaine in our study's prescribed dose and use was not recommended. There were also no reports of features attributable to lignocaine toxicity. Phlebitis could be avoided by assessing the injection site before running the potassium chloride infusion with lignocaine.
Another reason contributing to the infrequent use of lignocaine to reduce pain from potassium chloride infusion was medical error arising from an extra step in preparation. Errors had resulted when staff used the wrong formulation due to the different concentrations and preparations of lignocaine currently available. This should not be a reason to deny patients a simple intervention which could be carried out by trained staff adhering to stringent preparation protocols, as with many other medications being used in any hospitals.
Study limitations
The main limitation of this observational study was the lack of randomization of patients into receiving lignocaine prior to potassium chloride infusion. However, we attempted to control for this by the use of stabilized weights in the statistical analysis. Nonetheless, unidentified confounders may still exist, affecting the results.
Another limitation was that absolute occurrence of pain was tracked instead of pain score. Therefore, for patients who experienced pain during the infusion, we were unable to compare the difference in pain scores between the two groups. This decision was based on an ideal outcome, as the pretreatment with lignocaine should alleviate all pain associated with the infusion, removing the need for intervention from the attending staff. The extent of pain score reduction with lignocaine during potassium chloride infusion and its effectiveness would need to be evaluated in a separate study.
Conclusion
The addition of lignocaine to intravenous potassium chloride replacement was useful in reducing pain during the infusion process. This would improve patient acceptance of the therapy and also reduce the need for additional intervention from the attending staff. In addition, we have proven that this extra step in preparation could be done safely and the addition of lignocaine was not associated with any adverse events as previously thought. Therefore, we recommend the routine use of 3 ml of 1% lignocaine prior intravenous potassium chloride replacement as a new practice standard. 
